Breaking News
December 11, 2017 - MIT researchers discover new way to make bacteria vulnerable to existing antibiotics
December 11, 2017 - Office Workers Don’t Like Being Chained to Their Desks: MedlinePlus Health News
December 11, 2017 - Study reveals how a very low calorie diet can reverse type 2 diabetes
December 11, 2017 - University of Adelaide receives $23.2 million for preterm birth research
December 11, 2017 - Tough Flu Season Ahead: Vaccine May Only Be 10% Effective
December 11, 2017 - Getting Self-Driving Cars on the Road Soon Might Save Lives: MedlinePlus Health News
December 11, 2017 - Enterovirus vaccine prevents virus-induced diabetes in a T1D experimental model
December 11, 2017 - Solar retinopathy or sun damage to the eyes – a case report
December 11, 2017 - Cancer risk with birth control pills emerges again in latest study
December 10, 2017 - Deer Hunters: Put Safety First: MedlinePlus Health News
December 10, 2017 - High blood pressure is redefined as 130, not 140: US guidelines (Update)
December 10, 2017 - Unusual neuroinflammation may underlie cognitive problems in cART-treated HIV patients
December 10, 2017 - Racial differences in parents’ reports of child’s autism symptoms may contribute to delayed diagnosis
December 10, 2017 - Taurine could boost effectiveness of existing multiple sclerosis therapies
December 10, 2017 - The man with a young woman’s heart
December 10, 2017 - Patient bedside remains important component of medical education for students
December 10, 2017 - Nutrition labeling has little impact on sodium consumption
December 10, 2017 - ‘Obesity paradox’ not present among people with new cases of cardiovascular disease
December 10, 2017 - SLU scientists provide promising approach in designing new drugs for DMD
December 10, 2017 - Can PD-1 Inhibitor Help Eradicate HIV?
December 10, 2017 - Checking Prices for Medical Procedures Online? Good Luck: MedlinePlus Health News
December 10, 2017 - Researchers find bacteria tied to esophageal cancer
December 10, 2017 - Boy’s Double Hand Transplant Changed His Brain
December 10, 2017 - Memo to Doctors: Spit Out the Bad News: MedlinePlus Health News
December 10, 2017 - Two years of extended anastrozole therapy proved as effective as five years in clinical trial
December 10, 2017 - Using digital devices before bed may contribute to sleep and nutrition problems in children
December 10, 2017 - Are You Sure That’s What the Doctor Said About Your Leukemia?: MedlinePlus Health News
December 10, 2017 - Low vitamin D levels at birth linked to higher autism risk
December 10, 2017 - Alcohol use in movies influences onset of drinking among 10- to 15-year-olds
December 10, 2017 - For children with ADHD, a brief, school-based program can help dramatically with homework problems, study finds
December 10, 2017 - Surgical Residents Prime Candidates for Stress, Depression, Alcohol Abuse: MedlinePlus Health News
December 10, 2017 - Young athletes commonly develop bone marrow edema in the joints of the lower spine
December 10, 2017 - Coordinated approach in emergency care of heart attacks saves lives
December 10, 2017 - Patients OK With Fewer Opioids After Gallbladder Surgery
December 10, 2017 - Obamacare May Have Helped More Americans Quit Smoking: MedlinePlus Health News
December 10, 2017 - Long-term opioid use does not increase risk of Alzheimer ‘s disease
December 10, 2017 - Brief test can help determine whether drugs, talk therapy work better for treating anxiety
December 10, 2017 - Bioelectronic ‘nose’ can easily sniff foul smells in rotting food
December 10, 2017 - Spontaneous humor can be helpful for cancer patients to deal with distress
December 10, 2017 - Study finds mechanism of resistance to checkpoint inhibitors and way to reverse it
December 10, 2017 - ‘Lesser of two evils’ argument used to defend antipsychotic overuse for dementia
December 10, 2017 - Physical activity in middle age linked to lower incidence of joint symptoms
December 10, 2017 - Optogenetics research sheds new light on social-spatial learning
December 9, 2017 - Guidelines for MRI breast cancer screening not followed in community settings
December 9, 2017 - New first line combination therapy shows promising results in patients with advanced NSCLC
December 9, 2017 - Catheter-Directed Lysis Adds Risk, Not Benefit, for Proximal DVT
December 9, 2017 - Alzheimer’s Cases to Double by 2060: Report: MedlinePlus Health News
December 9, 2017 - New care model closes significant gap in addiction treatment
December 9, 2017 - PARP inhibitor can be new treatment option for patients with metastatic breast cancer, BRCA mutations
December 9, 2017 - Study shows how electrical stimulation in the brain instructs appropriate response
December 9, 2017 - Researchers develop molecular beacon to find hypoxic spots in real time
December 9, 2017 - Many Hospice Workers Lack Their Own End-of-Life Directives: MedlinePlus Health News
December 9, 2017 - New compound stops progressive kidney disease in its tracks
December 9, 2017 - Study: Changes in the brain after childhood limb loss can be reversed
December 9, 2017 - Semaglutide (Ozempic) Approved for Type 2 Diabetes
December 9, 2017 - Study Untangles Disparity in Colon Cancer Survival Rates: MedlinePlus Health News
December 9, 2017 - Lymph node surgery may raise risk of arm morbidity in younger women
December 9, 2017 - Study reveals connection between restless sleep and Parkinson’s disease
December 9, 2017 - Modern non-invasive diagnostics can get clear picture of the heart’s condition
December 9, 2017 - New method helps measure effect of one brain region on another in depression
December 9, 2017 - Mount Sinai study uses adaptive optics to examine retinal eye damage from solar eclipse
December 9, 2017 - Scientists introduce polyproline as effective cryoprotectant for monolayers of cells
December 9, 2017 - Simple molecular test may help predict presence of high-grade pancreatic cancers
December 9, 2017 - High levels of burnout, stress for U.S. surgical residents
December 9, 2017 - Parental lifespan genes could pave way for new therapeutic targets to prolong life
December 9, 2017 - About Half of Americans Get Health Care in ER: MedlinePlus Health News
December 9, 2017 - People with epilepsy may gain from common sleep apnea treatment
December 9, 2017 - Anti-impotence drug found to be ineffective at improving outcomes for IUGR pregnancies
December 9, 2017 - High risk of burnout, depression, and low quality of life found among health care workers
December 9, 2017 - Higher educational attainment associated with lower risk of Alzheimer’s disease
December 9, 2017 - Researchers seek to understand role of novel protein in tumor metastasis
December 9, 2017 - Research brings scientists one step closer to understanding development of ALS
December 9, 2017 - Women and Caregiving: Facts and Figures
December 9, 2017 - Mindfulness meditation found to relieve the stress of waiting for bad news
December 9, 2017 - Common fungus has significant impact on mosquitoes’ ability to transmit dengue virus
December 9, 2017 - Short online program improves ability of teen girls to communicate about safe sex
December 9, 2017 - Researcher discovers enzyme pathway involved in ALS pathogenesis
December 9, 2017 - Fusobacterium may play role in colon cancer growth, study finds
December 9, 2017 - Are Women Naturally Fitter Than Men?
December 9, 2017 - Celecoxib Strikes Out on Cancer Progression
Biohaven Reports Negative Topline Data From Spinocerebellar Ataxia (SCA) Phase 2/3 Trial

Biohaven Reports Negative Topline Data From Spinocerebellar Ataxia (SCA) Phase 2/3 Trial

image_pdfDownload PDFimage_print

New Haven, Connecticut (NYSE: BHVN) October 2, 2017 – Biohaven Pharmaceutical Holding Company Ltd. today reported topline results from its Phase 2/3 clinical trial evaluating trigriluzole compared to placebo for the treatment of patients with spinocerebellar ataxia (SCA). The eight-week trial dosed 141 adult SCA patients at 18 centers in the United States. In this trial, trigriluzole did not differentiate from placebo on the primary endpoint of the mean change from baseline on the Scale for the Assessment and Rating of Ataxia (SARA) after eight weeks of treatment.

After eight weeks of treatment, trigriluzole treated subjects demonstrated an improvement of -0.81 points [95% CI: -1.4 to -0.2] on the SARA versus -1.05 points [95% CI: -1.6 to -0.4] improvement in placebo, p-value = 0.52. Placebo response in this genetically defined disorder was higher than expected based upon prior European randomized controlled trials in SCA (Romano et al 2015; Ristori et al 2010).

In addition, trigriluzole did not differentiate on the key secondary efficacy endpoint of Patient’s Global Impression of Change (PGI-C). 50.8% of subjects treated with trigriluzole considered themselves improved versus 59.1% treated with placebo, p-value = 0.28.

However, trigriluzole did demonstrate a favorable safety and tolerability profile, with no drug-related serious adverse events and low discontinuation rates due to adverse events. Trigriluzole has shown absence of a negative food effect, optimized oral bioavailability and no pattern of clinically significant effects on liver function, presenting a profile that appears distinct from what is described for riluzole in its U.S. prescribing information.

Although this study failed to demonstrate acute symptomatic effects of trigriluzole in SCA, the long-term, open-label, extension phase is ongoing. This extension phase will allow for potential signal detection at later time points. Topline data from the extension phase is expected in 4Q 2018.

“We are obviously disappointed that today’s topline clinical results do not support continued development of trigriluzole as a symptomatic agent for patients with SCA, a devastating neurologic disorder for which novel treatments are urgently needed. This was the largest SCA clinical trial performed to date and important knowledge has been generated — we plan to share our data with the ataxia clinical leaders and the National Ataxia Foundation to help refine clinical trials in this therapeutic area. We thank the patients and clinical investigators who participated in this program and sincerely appreciate all that they have done to see this study through completion,” stated Vlad Coric, M.D., Chief Executive Officer of Biohaven.

Susan L. Perlman, M.D., Clinical Professor of Neurology and Director of the Ataxia Center and HD Center of Excellence at UCLA, stated, “Biohaven has accomplished something extremely important for patients with spinocerebellar ataxia (a chronic, progressive, incurable neurogenetic disorder) and for the doctors and scientists who work with these patients and families. The company mobilized 18 ataxia clinical research centers from around the United States, engaged them and trained them in a complex drug trial protocol, and was able to complete the protocol in a timely fashion and with excellent participation and safety outcomes. Biohaven is the first U.S. pharmaceutical company to advance into these uncharted waters for spinocerebellar ataxia and will lead the way for others in the future.”

Robert Berman, M.D., Chief Medical Officer of Biohaven added, “The Biohaven team had hoped this trial would bring a long-awaited treatment for patients with SCA and we are grateful for how the community of patients and researchers rallied around this trial, allowing us to enroll the study in under six months. While the efficacy results were unfortunately disappointing, this study did demonstrate important characteristics of trigriluzole, including a favorable safety and tolerability profile. For the first time, trigriluzole was dosed chronically for over 24 weeks in some patients.”

Dr. Coric continued, “We have a deep portfolio of clinic-ready compounds. With a strong cash position, we will continue to deploy our resources in what we believe is a cost effective and data driven fashion. Our team remains focused on progressing our other drug candidates within the CGRP (rimegepant and BHV-3500) and glutamate modulation platforms (BHV-0223 and BHV-5000).”

In its CGRP platform, the company anticipates a number of important upcoming milestones. Enrollment and randomization continue to proceed strongly in both of Biohaven’s Phase 3 clinical trials of rimegepant for the acute treatment of migraine, and the company expects to report topline results in the first quarter of 2018. The long-term safety study is expected to complete in the fourth quarter of 2018 to support a potential first half 2019 NDA submission. Biohaven also expects to file an IND with the FDA later this year for BHV-3500 for the treatment of migraine.

In its glutamate-modulation platform, Biohaven anticipates commencing a bioequivalence study for BHV-0223 for the treatment of patients with amyotrophic lateral sclerosis (ALS) in the fourth quarter of 2017. With regard to BHV-5000, a low trapping NMDA receptor antagonist in-licensed from AstraZeneca, the company continues to optimize its formulation to support a Phase 1 pharmacokinetic trial in Rett syndrome, as well as other neuropsychiatric indications. Biohaven will also continue its program to evaluate trigriluzole in non-movement disorders where the pathophysiology is distinct from SCA. On September 28, 2017, the FDA notified Biohaven that it may proceed with its Phase 2/3 trial of trigriluzole in OCD; the study is scheduled to enroll a first patient in the coming weeks.

About Biohaven

Biohaven is a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders. Biohaven has combined internal development and research with intellectual property licensed from companies and institutions including Bristol-Myers Squibb Company, AstraZeneca AB, Yale University, Catalent, Rutgers, ALS Biopharma LLC and Massachusetts General Hospital. Currently, Biohaven’s lead development programs include multiple compounds across its CGRP receptor antagonist and glutamate modulation platforms. Biohaven’s common shares are listed on the New York Stock Exchange and traded under the ticker symbol BHVN. More information about Biohaven is available at www.biohavenpharma.com.

Forward-Looking Statements

This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of the Company’s management. All statements, other than statements of historical facts, included in this press release, including statements regarding the Company’s expectations for the timing and reporting of data from its ongoing and planned clinical trials, the timing of regulatory filings and development timelines and the potential benefits of trigriluzole for patients with non-movement disorder indications are forward-looking statements. The use of certain words, including the words “believe,” “continue,” “expect”, “may” and “will” and similar expressions are intended to identify forward-looking statements. The Company may not actually achieve the plans and objectives disclosed in the forward-looking statements and you should not place undue reliance on the Company’s forward-looking statements. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by our forward-looking statements, including the significant risks and uncertainties regarding the future clinical success and regulatory pathway for the company’s product candidates. Additional important factors to be considered in connection with forward-looking statements are described in the “Risk Factors” section of the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 14, 2017. The forward-looking statements are made as of this date and the Company does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Source: ven Pharmaceutical Holding Company Ltd.

Posted: October 2017

Tagged with:

About author

Related Articles